Pfizer has agreed to acquire Ferrosan’s consumer healthcare business from Altor 2003 Fund GP.
The Denmark-based pharmaceutical company serves a broad European market including Russia, Ukraine, Poland, and Turkey.
Pfizer Consumer Healthcare president Paul Sturman said, “Ferrosan is an excellent strategic fit that strengthens our presence in dietary supplements with a new set of compelling brands and product pipeline.”
Ferrosan’s portfolio includes multivitamin brand multi-tabs, probiotic Bifiform and the Omega 3 supplement Flyt /Active Omega.
The transaction is subject to customary closing conditions and regulatory approval, but is expected to close during the second quarter of 2011. Financial terms have not been disclosed.
Share this article
